Irland - Englisch - HPRA (Health Products Regulatory Authority)

ltt pharma limited - budesonide, formoterol fumarate dihydrate - powder for inhalation - 400/12 mcg/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics - adrenergics and other drugs for obstructive airway diseases - it is indicated in adults and adolescents aged 12 to17 years for the regular treatment of asthma and for the symptomatic treatment of patients with severe copd

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - olaparib (unii: woh1jd9ar8) (olaparib - unii:woh1jd9ar8) - olaparib 50 mg - lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline brca -mutated (gbrcam ) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. none. risk summary based on findings in animals and its mechanism of action [see clinical pharmacology (12.1)] , lynparza can cause fetal harm when administered to a pregnant woman. there are no available data on lynparza use in pregnant women to inform the drug associated risk. in an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 400 mg twice daily [see data] . apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy. the estimated background risk of major birth d

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - water for injections -

Tansania - Englisch - Tanzania Medicinces & Medical Devices Authority

astrazeneca united kingdom limited, united kingdom - lisinopril , hydrochlorohiazide - tablets - 20mg + 12.5mg

Tansania - Englisch - Tanzania Medicinces & Medical Devices Authority

astrazeneca united kingdom limited, united kingdom - lisinopril - tablet, film-coated - 10mg

Tansania - Englisch - Tanzania Medicinces & Medical Devices Authority

astrazeneca united kingdom limited, united kingdom - lisinopril - tablets - 20mg

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 190mg;   - modified release tablet - 190 mg - active: metoprolol succinate 190mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 47.5mg;   - modified release tablet - 47.5 mg - active: metoprolol succinate 47.5mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 95mg;   - modified release tablet - 95 mg - active: metoprolol succinate 95mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 23.75mg;   - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension